Alerts will be sent to your verified email
Verify Email
PPLPHARMA
|
Piramal Pharma
|
Cohance Lifesciences
|
Suven Life Sciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Domestic Sales Growth - YoY
|
15.43 % | n/a | n/a |
|
R&D as a % of Total Sales
|
0.71 % | 1.57 % | 1683.57 % |
|
Financials
|
|||
|
5 yr Average ROE
|
4.5 % | 27.26 % | -65.97 % |
|
5yr average Equity Multiplier
|
1.97 | 1.3 | 1.69 |
|
5yr Average Asset Turnover Ratio
|
0.53 | 0.61 | 0.05 |
|
5yr Avg Net Profit Margin
|
4.14 % | 33.51 % | -798.21 % |
|
Price to Book
|
3.19 | 22.38 | 47.0 |
|
P/E
|
284.51 | 141.75 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
-17.8 Days | 70.98 Days | 54.79 Days |
|
Inventory Days
|
68.38 Days | 76.62 Days | 5.7 Days |
|
Days Receivable
|
76.2 Days | 42.46 Days | 32.67 Days |
|
Days Payable
|
156.5 Days | 85.69 Days | 7.08 Days |
|
5yr Average Interest Coverage Ratio
|
3.08 | 47.81 | -218.98 |
|
5yr Avg ROCE
|
6.74 % | 32.61 % | -67.21 % |
|
5yr Avg Operating Profit Margin
|
15.07 % | 43.1 % | -890.08 % |
|
5 yr average Debt to Equity
|
0.63 | 0.09 | 0.01 |
|
5yr CAGR Net Profit
|
-53.67 % | -1.08 % | 2.21 % |
|
5yr Average Return on Assets
|
2.39 % | 20.57 % | -37.69 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
34.95 % | 50.1 % | 70.27 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.16 % | -9.9 % | 5.29 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
12.19 % | 7.13 % | 0.0 |
|
Piramal Pharma
|
Cohance Lifesciences
|
Suven Life Sciences
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Services Break-Up
|
Services Break-Up
|
-
|
-
|